key: cord-0713159-z9y3la43 authors: Negro, Enrica; Mardigyan, Vartan; Trotta, Lucia; Pancrazi, Massimo; Bizzi, Emanuele; Brenna, Martino; Imazio, Massimo; Brucato, Antonio title: Commentary on “Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID‐19: A Case Series.”: COVID‐19 disease in patients with recurrent pericarditis during treatment with anakinra date: 2021-03-01 journal: Arthritis Rheumatol DOI: 10.1002/art.41702 sha: 2e007bfb0ea9e8ccde0e44bd9425f2a032ab6126 doc_id: 713159 cord_uid: z9y3la43 We read with interest the paper from Navarro‐Millan about the use of anakinra in severe COVID‐19 patients (1). On the other hand, there is the issue of patients treated with anakinra for their underlying condition and who develop COVID‐19 (2). Other authors have no disclosures. We read with interest the paper from Navarro-Millan about the use of anakinra in severe COVID-19 patients (1) . On the other hand, there is the issue of patients treated with anakinra for their underlying condition and who develop COVID-19 (2). We describe here five patients, median age 43 year, with recurrent pericarditis (RP) (post-pericardiotomy in 1 case, idiopathic in 4 cases), who had COVID-19 disease during treatment with anakinra. Median duration of RP was 48 months. All the subjects were treated with anakinra after an initial treatment with corticosteroids, NSAIDs and colchicine (Table 1) . This article is protected by copyright. All rights reserved The patients developed COVID-19 disease between March 2020 and October 2020. Symptoms, usually mild, included fever, cough, ageusia, anosmia, headache, diarrhoea, dyspnoea and chest pain (Table 1) . Four subjects tested positive for SARS-CoV2 nasopharyngeal swab and one for SARS-CoV2 serological test after symptoms. Two patients went to the emergency room and chest-X ray showed a small lung infiltrate in one case, but no hospitalization was required. Therapy with anakinra was maintained unchanged. Three patients added therapies during COVID-19 disease ( Table 1 ). All patients recovered completely within 15 days and had no recurrence of pericarditis. Polytherapy is often necessary in patients with RP, and therapy with an anti-IL1 agent may be resolutive (3); a concern may be raised that this biological therapy might aggravate the clinical course of coronavirus-19 disease. Our small series show that anakinra therapy in patients with RP may be associated with a benign clinical course. We propose that there is no reason to discontinue anakinra therapy if a patient with RP develop COVID-19 disease (4) (5) (6) (7) . This is in agreement with the findings of Navarro-Millan (1). Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-analysis The Longitudinal Immune Response to Coronavirus Disease 2019: Chasing the Cytokine Storm Accepted Article This article is protected by copyright. All rights reserved 6 Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID -19 pneumonia and moderate hyperinflammation . A retrospective cohort study